The estimated Net Worth of Henric Bjorn Bjarke is at least 1.13 百万$ dollars as of 15 December 2022. Mr Bjarke owns over 21,500 units of Inozyme Pharma stock worth over 549,348$ and over the last 8 years he sold INZY stock worth over 0$. In addition, he makes 576,877$ as Sr. VP & COO at Inozyme Pharma.
Mr has made over 2 trades of the Inozyme Pharma stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 21,500 units of INZY stock worth 29,885$ on 15 December 2022.
The largest trade he's ever made was buying 27,100 units of Inozyme Pharma stock on 19 April 2022 worth over 99,999$. On average, Mr trades about 6,075 units every 30 days since 2017. As of 15 December 2022 he still owns at least 105,441 units of Inozyme Pharma stock.
You can see the complete history of Mr Bjarke stock trades at the bottom of the page.
Henric Bjorn Bjarke is the Sr. VP & COO at Inozyme Pharma.
As the Sr. VP & COO of Inozyme Pharma, the total compensation of Mr Bjarke at Inozyme Pharma is 576,877$. There are 2 executives at Inozyme Pharma getting paid more, with Axel Bolte M.B.A., M.Sc. having the highest compensation of 771,398$.
Mr Bjarke is 54, he's been the Sr. VP & COO of Inozyme Pharma since . There are 3 older and 2 younger executives at Inozyme Pharma. The oldest executive at Inozyme Pharma, Inc. is Dr. Pedro Huertas, 64, who is the Sr. VP & Chief Medical Officer.
Henric's mailing address filed with the SEC is C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON, MA, 02210.
Over the last 4 years, insiders at Inozyme Pharma have traded over 0$ worth of Inozyme Pharma stock and bought 11,149,230 units worth 104,131,475$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of 2,019,505$. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth 130,250$.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma executives and other stock owners filed with the SEC include: